Roche NimbleGen said today that genomic services provider Ambry Genetics has become a certified service provider for the NimbleGen SeqCap EZ Exome workflow.
Ambry, based in Aliso Viejo, Calif., will provide target enrichment services using SeqCap EZ Human Exome combined with next-generation sequencing services.
The SeqCap EZ Exome technology uses a single tube of stable DNA oligos to capture all exons in solution in a simple, scalable workflow, and contains 2.1 million empirically optimized DNA probes, according to Roche NimbleGen.
Under the partnership, Ambry will process customer genomic DNA samples for enrichment using SeqCap to capture all human coding exons, and sequence the enriched samples using short-read, paired-end sequencing, Roche NimbleGen said.
Ambry becomes Roche NimbleGen's first service provider in the US, the companies said.
Roche NimbleGen CEO Frank Pitzer said in a statement that Ambry's genomics and next-gen sequencing services were "an ideal fit" with the SeqCap EZ Exome technology, and that the partnership will provide more researchers with access to the technology.